116 related articles for article (PubMed ID: 12505132)
1. Cerebral metabolism and risperidone treatment in schizophrenia.
Molina V; Gispert JD; Reig S; Sanz J; Pascau J; Santos A; Palomo T; Desco M
Schizophr Res; 2003 Mar; 60(1):1-7. PubMed ID: 12505132
[TBL] [Abstract][Full Text] [Related]
2. Cerebral metabolic patterns in chronic and recent-onset schizophrenia.
Desco M; Gispert JD; Reig S; Sanz J; Pascau J; Sarramea F; Benito C; Santos A; Palomo T; Molina V
Psychiatry Res; 2003 Feb; 122(2):125-35. PubMed ID: 12714176
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
Smesny S; Langbein K; Rzanny R; Gussew A; Burmeister HP; Reichenbach JR; Sauer H
Schizophr Res; 2012 Jul; 138(2-3):164-70. PubMed ID: 22516552
[TBL] [Abstract][Full Text] [Related]
4. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.
Molina V; Gispert JD; Reig S; Sanz J; Pascau J; Santos A; Desco M; Palomo T
Psychopharmacology (Berl); 2005 Feb; 178(1):17-26. PubMed ID: 15365682
[TBL] [Abstract][Full Text] [Related]
5. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
6. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
Holcomb HH; Cascella NG; Thaker GK; Medoff DR; Dannals RF; Tamminga CA
Am J Psychiatry; 1996 Jan; 153(1):41-9. PubMed ID: 8540590
[TBL] [Abstract][Full Text] [Related]
7. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
9. Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients.
Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
J Psychiatr Res; 2008 Mar; 42(4):328-35. PubMed ID: 17412363
[TBL] [Abstract][Full Text] [Related]
10. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
12. Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Roiz-Santiáñez R; Tordesillas-Gutiérrez D; Ortíz-García de la Foz V; Ayesa-Arriola R; Gutiérrez A; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2012 Oct; 141(1):22-8. PubMed ID: 22884754
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
14. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
15. [Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
Künstler U; Hohdorf K; Regenthal R; Seese A; Gertz HJ
Nervenarzt; 2000 May; 71(5):373-9. PubMed ID: 10846712
[TBL] [Abstract][Full Text] [Related]
16. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Marder SR; Davis JM; Chouinard G
J Clin Psychiatry; 1997 Dec; 58(12):538-46. PubMed ID: 9448657
[TBL] [Abstract][Full Text] [Related]
17. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
Rabinowitz J; Hornik T; Davidson M
J Clin Psychiatry; 2001 May; 62(5):343-6. PubMed ID: 11411815
[TBL] [Abstract][Full Text] [Related]
18. Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Garver DL; Holcomb JA; Christensen JD
Biol Psychiatry; 2005 Jul; 58(1):62-6. PubMed ID: 15992524
[TBL] [Abstract][Full Text] [Related]
19. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
[TBL] [Abstract][Full Text] [Related]
20. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
Williams LM; Loughland CM; Green MJ; Harris AW; Gordon E
Psychiatry Res; 2003 Aug; 120(1):13-27. PubMed ID: 14500110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
